Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02007252
Other study ID # CACZ885X2201
Secondary ID 2013-002088-25
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 2013
Est. completion date October 2015

Study information

Verified date March 2019
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.


Recruitment information / eligibility

Status Terminated
Enrollment 65
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Key Inclusion Criteria: 1. Male and female subjects age =45 years of age 2. Infrarenal abdominal aortic aneurysm with maximum diameter: for men =40mm and =50mm; for women =38mm and =48mm. 3. On a stable medical regimen for at least 2 weeks prior to dosing, per investigator assessment. 4. Have an evaluable ultrasound image at screening for the quantitative determination of the AAA size, per imaging core lab assessment. 5. At screening, vital signs should be within the following ranges: (a) oral body temperature between 35.0-37.5°C; (b) systolic blood pressure, 90-170 mm Hg; (c) diastolic blood pressure, 50-100 mm Hg; (d) pulse rate, 40 - 100 bpm. Key Exclusion Criteria: 1. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment. 2. Known diabetes by medical history, an HbA1c of =6.5% at screening, or on an active diabetic medical regimen. 3. History of malignancy of any organ system other than localized basal cell carcinoma of the skin, treated or untreated, within the past 5 years. 4. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and 30-day follow up period of the study. 5. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation. 6. Subjects on the following medications: (a) Chronic systemic steroid treatment or other systemic immunosuppression; (b) Any biologic drugs targeting the immune system, along with a history of any previous use of such drugs. 7. Presence of a non-healing wound or infection, including active urinary tract infections, or any recent process requiring significant tissue healing per investigator assessment. 8. Significant illness which has not resolved within four (4) weeks prior to initial dosing or with a life expectancy less than 2 years. 9. Any of the following concomitant hepatic or renal conditions or diseases: (a) Nephrotic syndrome, or eGFR less than 30 mL/min/1.73 m2 per CRCL formula; (b) Prior organ transplant requiring immunosuppressive therapy; (c) Known active or recurrent hepatic disorder. 10. Previous infra-renal aortic surgery 11. Planned major surgery 12. Known aortic dissection 13. Subjects with eligible AAA diameter, but with known slow growth (<2mm/year) or known stable AAA size over the prior one year of surveillance per investigator assessment. 14. Subjects should exhibit no signs of clinically concerning unstable acceleration of AAA size or growth rate at the time of enrollment per investigator assessment. 15. Known or suspected inherited connective tissue disorders (e.g., Marfan or Vascular Ehlers Danlos syndrome). 16. Recently unstable clinically significant cardiac disease within 3 months of screening, including but not limited to, unstable angina, acute myocardial infarction, and congestive heart failure (NYHA class IV). 17. Uncontrolled or refractory hypertension per Investigator determination. 18. Live vaccinations within 3 months prior to randomization, or live vaccinations planned during the study. 19. History of untreated tuberculosis infection or evidence of active tuberculosis (TB) infection. 20. History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study. 21. History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. 22. A positive Hepatitis B surface antigen or Hepatitis C test result whether at screening or historically. 23. For USA sites utilizing CT angiograms, subjects with a history of a previous reaction to contrast agent, a known sensitivity to iodine and known allergies (e.g, shellfish allergy), or other hypersensitivities to contrast agents. 24. Underlying immune disorders, autoimmunity or immunodeficiency. 25. History of drug or alcohol abuse within the 12 months prior to dosing.

Study Design


Intervention

Drug:
ACZ885
ACZ885 150 mg liquid pre-filled syringes were administered s.c..
Placebo
Matching placebo liquid pre-filled syringes were administered s.c..

Locations

Country Name City State
Denmark Novartis Investigative Site Copenhagen
Denmark Novartis Investigative Site Kolding
Denmark Novartis Investigative Site Odense C
Netherlands Novartis Investigative Site Amsterdam
Netherlands Novartis Investigative Site Eindhoven
Sweden Novartis Investigative Site Orebro
Sweden Novartis Investigative Site Stockholm
United Kingdom Novartis Investigative Site Manchester
United States Novartis Investigative Site Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Denmark,  Netherlands,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Abdominal Aortic Aneurysm (AAA) Size Per Year Size of the AAA was determined using an abdominal ultrasound technique at baseline, 3 months, and 12 months after treatment with study drug. Growth rate (in mm/year) was calculated from the change in AAA size compared to baseline month 3, month 12
See also
  Status Clinical Trial Phase
Completed NCT01480206 - Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR
Active, not recruiting NCT03743142 - Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis In the Treatment of Abdominal Aortic Aneurysms
Terminated NCT04592991 - CCR2 AAA Pilot Study Early Phase 1
Active, not recruiting NCT02009644 - Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms N/A
Completed NCT01990950 - Fenestrated AAA Endovascular Graft Post-Approval Study N/A
Withdrawn NCT04551183 - Comparative Study of a Software With the Gold Standard N/A
Completed NCT02306304 - Ultra-sound for AAA Screening in Smoking Israeli Arab Men N/A
Recruiting NCT02295137 - Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair Phase 1
Recruiting NCT04586452 - NIH CCR2 AAA Study Early Phase 1
Completed NCT01726257 - Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System N/A
Completed NCT02934087 - Endovascular Aneurysm Repair (EVAR) Gate Study N/A
Terminated NCT03231397 - Predictors of AAA Expansion and/or Rupture Phase 4
Completed NCT04333641 - Development of Novel Imaging Markers Predicting the Progression of Abdominal Aortic Aneurysm Using 3D Computed Tomography